Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

Abstract

By combining deep learning technology and CT images, we developed an individual non-invasive biomarker that could distinguish High-TMB from Low-TMB, which might inform decisions on the use of ICIs in patients with advanced NSCLC.